Nuvation Bio Inc.

Nuvation Bio Inc. (NYSE: NUVB) is a clinical-stage biopharmaceutical company focused on developing novel oncology therapeutics that reached public markets through a de-SPAC merger with Panacea Acquisition Corp. II, a healthcare-focused blank-check vehicle sponsored by Panacea Holdings, LLC, which priced its IPO in 2021. The business combination closed in early 2022, listing Nuvation Bio on the New York Stock Exchange under the ticker NUVB. Founded by oncology entrepreneur David Hung, the company continues to advance a precision cancer pipeline across multiple clinical programs. Nuvation Bio filed an 8-K current report with the SEC on May 27, 2026. For complete filings history, sponsor detail, and real-time SPAC analytics on NUVB, sign up for SpacDesk.